<DOC>
	<DOCNO>NCT01134380</DOCNO>
	<brief_summary>The objective GIANT Study evaluate clinical impact genetic resistance thienopyridine profile determination ( CYP2C19 gene ) clinical impact compliance adjust thienopyridine treatment STEMI patient treat primary PCI within 24 hour follow first chest pain .</brief_summary>
	<brief_title>Genotyping Infarct Patients Adjust Normalize Thienopyridine Treatment</brief_title>
	<detailed_description>All STEMI patient treat primary PCI ( stent implantation ) within 24 hour follow first chest pain include GIANT study . After PCI , 'll receive DAT ( Aspirin + Clopidogrel/Prasugrel ) . Patients genotyped determine carry one CYP2C19 gene variant make resistant hyper responder clopidogrel . The genetic profile patient communicate physician take care ( ) adjust thienopyridine treatment ( increase clopidogrel dosage , switch prasugrel switch clopidogrel ) . A treatment prescribed 12 month accord European guideline . One year PCI , patient available follow visit . They 'll submit VERIFY NOW P2Y12 protocol determine whether compliant thienopyridine treatment . A clinical follow also perform evaluate cardiovascular event .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>STEMI patient treat within first 24 hour primary PCI ( stent implantation ) Age superior equal 18 year old Informed consent sign Patient volunteer submit 1 year visit follow clinical exam visit Patient benefit French social health system NONSTEMI patient high troponin STEMI patient treat first 24 hour Stable / unstable angina silent ischemia Cardiogenic shock Oral anticoagulation ( Vitamin K Antagonists ) Contraindication PCI Age inferior 18 year old Life expectancy inferior 1 year Participation another clinical trial No sign inform consent Patient available 1 year visit follow Pregnant woman Known allergy medium contrast control adapted treatment Known allergy cobalt chromium alloy Left ventricular ejection fraction lower 30 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Dual antiplatelet therapy</keyword>
	<keyword>clopidogrel/prasugrel</keyword>
	<keyword>genotyping</keyword>
	<keyword>stent</keyword>
	<keyword>compliance</keyword>
</DOC>